ARCA BIOPHARMA ANNOUNCES COMPLETION OF FDA PRE-IND CONSULTATION UNDER CORONAVIRUS TREATMENT ACCELERATION PROGRAM FOR AB201 AS A POTENTIAL TREATMENT FOR SEVERE COVID-19
AB201-COVID-Pre-IND-Completed
Recent Posts
ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split
ARCA biopharma Provides Update Regarding Special Dividend Amount in Connectionwith the Proposed Merger with Oruka Therapeutics
ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics
ARCA biopharma Declares Special Dividend in Connection with the Proposed Mergerwith Oruka Therapeutics
ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Archives
August 2024
April 2024
February 2024
October 2023
July 2023
April 2023
March 2023
December 2022
October 2022
August 2022
June 2022
May 2022
April 2022
March 2022
January 2022
December 2021
November 2021
October 2021
September 2021
August 2021
July 2021
May 2021
March 2021
December 2020
November 2020
October 2020
September 2020
August 2020
July 2020
June 2020
May 2020
February 2020
November 2019
September 2019
August 2019
May 2019
April 2019
March 2019
February 2019
December 2018
November 2018
September 2018
August 2018
July 2018
May 2018
April 2018
March 2018
February 2018
January 2018
November 2017
September 2017
August 2017
June 2017
May 2017
April 2017
March 2017
February 2017
January 2017
November 2016
October 2016
August 2016
May 2016
April 2016
March 2016
January 2016
November 2015
September 2015
August 2015
June 2015
Categories
Press Release
Uncategorized
